Bradley Carver is the founder of Syndevrx. Syndevrx has raised $1M in total funding. Latest round: Series C. Based in United States.
Brad Carver is the Co-founder, President and CEO of SynDevRx, Inc. SynDevRx is a biotechnology company focused on developing treatments for patients whose cancer is associated with metabolic dysfunction. Their lead asset SDX-7320/evexomostat has advanced into phase I and phase Ib/II clinical studies.
Full founder directory · Investor directory · Company funding database · Fundraising library